The purpose of this study is to compare the usual treatment with T-DM1 alone to T-DM1 plus tucatinib.
Learn more about the A011801 trial or call the Cancer Research Office at Phoenixville Hospital (610-983-1811), Pottstown Hospital (610-327-7772), or Reading Hospital (484-628-8193).